Apatinib, an inhibitor of VEGFR, and bevacizumab, humanized anti-VEGF monoclonal antibodies, have been used to treat non-small-cell lung cancer combined with PD-L1 antibody or chemotherapy (28). The gene discussed is KDR; the disease is non-small cell lung carcinoma.